Valuation: Repare Therapeutics Inc.

Market Cap 112M 98.36M 91.6M 84.25M 158M 10.71B 161M 1.09B 425M 5.31B 421M 412M 18.35B P/E 2023
-3.28x
P/E 2024 -0.66x
Enterprise Value -38.78M -34.03M -31.69M -29.15M -54.64M -3.7B -55.57M -376M -147M -1.84B -146M -142M -6.35B EV / Sales 2023
1,707,888x
EV / Sales 2024 -1,779,624x
Free-Float
99.77%
Yield 2023 *
-
Yield 2024 -
1 day+0.76%
Current year+1.92%
Current year 2.5
Extreme 2.5
2.65
1 year 1.48
Extreme 1.48
2.66
3 years 0.89
Extreme 0.89
13.85
5 years 0.89
Extreme 0.89
35.75
10 years 0.89
Extreme 0.89
46.44
Manager TitleAgeSince
President - 27/01/2026
Director TitleAgeSince
Director/Board Member - 27/01/2026
Date Insider Type Main position Quantity % Market Cap.
28/01/26 Issuer sale

Director

45,941 0.1066%
28/01/26 Issuer sale

Controller/Auditor

82,122 0.1905%
28/01/26 Issuer sale

Chief Executive Officer

1,167,586 2.7085%
Change 5-day change 1-year change 3-year change Capi.($)
+0.76%-.--%+67.72%-71.41% 114M
+0.18%+4.92%-3.00%+11.40% 47.88B
-2.24%+0.31%+393.45%+615.13% 39.09B
+1.40%+3.69%+12.21%+46.79% 36.75B
+13.94%+20.49%+22.85%+7.42% 40.55B
-0.73%+3.38%+4.94%+41.45% 27.96B
+0.40%-0.30% - - 16.77B
-3.12%+7.39%+26.03%+124.08% 15.94B
-1.90%-4.73%+1.11%+7.45% 13.55B
+6.79%+8.17%-4.97%-28.52% 13.81B
Average +1.55%+4.17%+57.82%+83.75% 25.24B
Weighted average by Cap. +2.15%+5.03%+72.65%+124.97%

Financials

2023 2024
Net sales 51.13 44.87 41.79 38.43 72.05 4.89K 73.28 495.75 194.04 2.42K 191.96 187.82 8.37K 53.48 46.93 43.7 40.2 75.35 5.11K 76.64 518.48 202.94 2.53K 200.76 196.43 8.75K
Net income -93.8M -82.32M -76.65M -70.5M -132M -8.96B -134M -909M -356M -4.44B -352M -345M -15.35B -84.69M -74.32M -69.21M -63.66M -119M -8.09B -121M -821M -321M -4.01B -318M -311M -13.86B
Net Debt -220M -193M -180M -166M -310M -21.04B -316M -2.14B -836M -10.43B -827M -809M -36.05B -151M -132M -123M -113M -213M -14.41B -216M -1.46B -572M -7.15B -566M -554M -24.7B
Logo Repare Therapeutics Inc.
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Employees
129
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. RPTX Stock